Business Wire

CA-PULMONX

Share
Pulmonary Experts Recommend Zephyr Endobronchial Valve (EBV) from Pulmonx as Only Minimally-Invasive Emphysema Treatment to Be Used Outside Clinical Trials

Pulmonx ®, a leader in interventional pulmonology, today announced publication of an expert panel recommendation in Respiration which concluded that only the company’s minimally-invasive Zephyr® Endobronchial Valve (EBV) and invasive lung volume reduction surgery (LVRS) “reached the evidence level to be used outside of clinical trials” for the treatment of severe emphysema. Their findings were based on a systematic review and meta-analysis of clinical evidence to date for six different therapies: lung volume reduction surgery (LVRS), EBV, coils, intra bronchial valves (IBV), thermal vapor ablation (steam) and biological lung volume reduction.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160309006190/en/

The expert panel of pulmonologists were:

  • Professor Felix Herth, MD, PhD, FCCP, Chairman and Head of Pneumology and Respiratory Care, Thoraxklinik, University of Heidelberg, Heidelberg, Germany
  • Klaus Rabe, MD, PhD, Professor of Pulmonary Medicine, University of Kiel and Director of the Department of Pneumology, Clinic Grosshansdorf, Ratzeburg, Germany
  • Pallav Shah, MD, MBBS, FRCP, Consultant Physician, The Royal Brompton Hospital and Chelsea & Westminster Hospital, London, UK
  • Dirk-Jan Slebos, MD, PhD, Department of Pulmonary Diseases and the Groningen Research Institute for Asthma and COPD, University Medical Center Groningen, Groningen, The Netherlands

The Zephyr EBV is the best studied of these options to-date, with three completed randomized controlled trials - STELVIO 1 , BeLieVeR-HIFi 2 and VENT 3,4 . These studies have demonstrated significant improvements in lung function, exercise capacity and quality of life in patients who are treated with the Zephyr EBV, with greater benefit in patients with low collateral ventilation1,2,3,4 . In the expert panel recommendation, the authors also note that two small long-term series have been published on the valves, both of which showed “a significant survival benefit in the successfully treated compared to the unsuccessfully treated group.”

The STELVIO trial, recently published in the New England Journal of Medicine , was the first randomized, controlled trial of Zephyr EBV therapy that used the Chartis® System to identify patients most likely to benefit. It also demonstrated in a prospective trial that Zephyr EBV therapy benefits a broad range of advanced stage emphysema patients, including those with heterogeneous disease and those with homogeneous disease1 .

In the expert panel recommendation in Respiration , the authors state that, “when taking all these trials together, evidence is accumulating that with EBV treatment, real personalized medicine for the treatment of patients with severe emphysema is possible, with even as high as a 75 percent responder rate to treatment when using a combined approach for recruiting potential candidates: assessment of fissure integrity to preselect patients, and (confirmation) of the absence of collateral flow with (the) Chartis (System).” In addition, the Panel reiterated that valves remain “the only removable endoscopic lung volume reduction technique.”

The Zephyr EBV is a tiny, one-way valve placed in the lungs to block airflow to diseased regions in order to achieve lung volume reduction. The Chartis System is a proprietary diagnostic utilized immediately prior to the Zephyr EBV procedure to identify those patients with low or no collateral ventilation, who are the most likely to respond to the treatment. Zephyr EBVs have been implanted globally in more than 10,000 patients. To view a video of the Zephyr EBV procedure, click here .

The Zephyr EBV is approved in over thirty countries outside the United States. For more information on patient eligibility and local hospitals offering the procedure, visit www.pulmonx.com .

About Pulmonx

Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com .

  1. Klooster K, Ten Hacken NHT, Hartman JE, Kerstjens HAM, Van Rikxoort EM, Slebos DJ. Endobronchial Valves for emphysema without interlobar collateral ventilation. N Engl J Med 2015; 373:2325-2335.
  2. Davey C, Zoumot Z, Jordan S, McNulty W, Carr D, Hind M, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet 2015; 386:1066–73; [Epub ahead of print: http://dx.doi.org/10.1016/S0140- 6736(15)60001-0 (including supplementary appendix)].
  3. Sciurba FC, Ernst A, Herth FJF, Strange C, Criner G, Marquette C, et al. A Randomized Study of Endobronchial Valves for Advanced Emphysema. N Engl J Med 2010; 363: 1233-1244 (including supplementary appendix).
  4. Herth F, Noppen M, Valipour A, Leroy S, Vergnon J-M, Ficker JH, Egan E, Gasparini S, Agusti C, Homes-Higgin D, Ernst A on behalf of the International VENT Study Group. Efficacy predictors of endoscopic lung volume reduction with Zephyr valves in a European cohort with emphysema. Eur Respir J 2012; 39: 1334-1342.

Contact:

Chronic Communications
Michelle McAdam
949-545-6654 or 310-902-1274
michelle@chronic-comm.com

Social Media:

http://www.facebook.com/Pulmonx-250712428387404/?ref=hl

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Clarity AI Acquires ecolytiq, Further Expanding Its AI Sustainability Solutions to End Consumers9.7.2025 13:00:00 CEST | Press release

The acquisition expands on Clarity AI’s market leading climate engagement offering for global retail and commercial banking financial institutions Clarity AI, one of the world’s largest and most awarded technology and AI firms in sustainability, today announced the acquisition of ecolytiq, a leading provider of in-app climate engagement solutions for financial institutions and their millions of retail and commercial banking customers globally. This strategic move further reinforces Clarity AI’s position at the forefront of the rapidly expanding sustainability tech sector, strengthening its dominance in delivering impactful, data-driven solutions that empower individuals and organizations to make more sustainable choices. With this acquisition, Clarity AI expands its class-leading product portfolio, serving a broad spectrum of market participants—from institutional investors and global corporations to retail banks and individual consumers. The company’s modular, AI-powered platform is d

Valorem Reply Brings AI-powered Image Recognition to Art Basel’s Global Fairs9.7.2025 12:57:00 CEST | Press release

Valorem Reply, part of the Reply Group and focused on delivering innovative digital solutions with Microsoft technologies, partnered with Art Basel – a premier international art fair that hosts shows in Basel, Hong Kong, Miami Beach, Paris and Qatar – to enhance the visitor experience. In partnership with Microsoft, they developed Art Basel Lens, a feature within the Art Basel Companion app that uses image recognition to provide real-time information about artworks directly to visitors’ smartphones, making it easier to explore and engage with the art on display. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709262853/en/ With Valorem Reply, Art Basel introduced a mobile image recognition feature that connects audiences to artworks using Microsoft Azure. By scanning an artwork, visitors receive structured content about the piece, the artist, and the gallery. The feature supports a more autonomous and fluid exploration of

Venture Global andSEFEAnnounceExpansion of LNG Partnership9.7.2025 12:19:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) and Securing Energy for Europe GmbH (SEFE) announced the finalization of an agreement under which SEFE’s subsidiary, SEFE Energy GmbH, will purchase an additional 0.75 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from CP2 LNG, Venture Global’s third project, for 20 years. Today’s announcement amends the existing Sales and Purchase Agreement signed by the companies in 2023, increasing the total volume of LNG purchased by SEFE from CP2 LNG to 3.0 MTPA. Venture Global is expected to become Germany’s largest LNG supplier, with a combined 5 MTPA of 20-year offtake agreements signed with SEFE and EnBW. In addition to its existing long-term agreements, Venture Global to date has supplied Germany with almost 80 cargoes of LNG from its Calcasieu Pass and Plaquemines LNG facilities, enough to power 8 million German homes for one year. “Venture Global is thrilled to expand our strategic partnership with Germany and SEFE and play a leading r

The MasterFrame 600, Cooler Master's Modular Full Tower for High-End Builds, Now Available in Europe9.7.2025 10:02:00 CEST | Press release

Inspired by the FreeForm 2.0 philosophy, this revolutionary open-frame chassis is now available across Europe at an MSRP of €199 Cooler Master, a global leader in PC hardware and innovative thermal solutions, today announced the European sales kick-off of the MasterFrame 600, a high-end, modular open-frame full tower designed for power users, creators, and PC modders seeking total creative freedom and high-performance potential. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709203901/en/ Cooler Master's MasterFrame 600 is built on our FreeForm 2.0 philosophy offering owners more customization options for personal builds. The MasterFrame 600 is available across Europe at a suggested retail price of €199, exclusively through select partners and resellers. Engineered on Cooler Master’s FreeForm 2.0 platform, the MasterFrame 600 redefines what’s possible in a premium PC chassis. This open-frame full tower delivers exceptiona

Kaneka Obtains Halal Certificate for KANEKA UBIQUINOL TM9.7.2025 03:30:00 CEST | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii) (TOKYO:4118) has obtained “Halal Certificate (Certification Number: 355-TSRI/24)” for its functional food ingredient, KANEKA UBIQUINOLTM (active form of coenzyme Q10) powder, under the assessment of Shariah Research Institute of Takushoku University, and issued by JAPAN MUSLIM ASSOCIATION, a religious corporation, on May 28. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708279133/en/ Halal certificate Halal certification is a system in which relevant organizations verify that products or services do not contain ingredients prohibited under Shariah (Islamic law) and certify their compliance with Shariah. We actively pursue the acquisition of various certifications to ensure the safety and security of our raw materials, and we are pleased to announce that we have obtained a Halal Certificate for KANEKA UBIQUINOLTM. Currently, the Muslim populati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye